Literature DB >> 9875652

Combination therapy of chronic hepatitis C: an important step but not the final goal!

H Wedemeyer, W H Caselmann, M P Manns.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9875652     DOI： 10.1016/s0168-8278(98)80133-5

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  4 in total

1.  Design, delivery and efficacy testing of therapeutic nucleic acidsused to inhibit hepatitis C virus gene expression in vitro and in vivo.

Authors:  Wolfgang H Caselmann; Matthias Serwe; Thomas Lehmann; Jnos Ludwig; Brian S Sproat; Joachim W Engels
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

2.  Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.

Authors:  Ann D Kwong; Robert S Kauffman; Patricia Hurter; Peter Mueller
Journal:  Nat Biotechnol       Date:  2011-11-08       Impact factor: 54.908

3.  Interleukin 6 and 12, alanine aminotransferase activity, and HCV viral load in children with chronic hepatitis C treated with interferon and ribavirin.

Authors:  Arleta Kowala-Piaskowska; Iwona Mozer-Lisewska; Magdalena Figlerowicz; Ludomiła Machowska; Wojciech Słuzewski
Journal:  Inflammation       Date:  2004-12       Impact factor: 4.092

4.  Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon.

Authors:  W Markland; T J McQuaid; J Jain; A D Kwong
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.